吉祥坊登录

Ultra Low Profile AAA Stent-Graft System ("Ultra Low Profile"), an endovascular device in-house developed by MicroPort Endovascular (Shanghai) Co ("MicroPort Endovascular"), a subsidiary of Shanghai MicroPort Medical (Group) Co ("MicroPort"), recently completed its first clinical implantation in Shanghai-based Zhongshan Hospital.

MicroPort's Ultra Low Profile is designed to treat abdominal aortic aneurysm ("AAA"), the most common form of aortic aneurysm which occurs most commonly in individuals between 65 and 75 years old, especially men and smokers. As the new generation of our AAA stent graft, Ultra Low Profile is the first and only of its kind with an outer sheath of delivery system as low as 14F in China.

The first implantation of Ultra Low Profile, done by Dr. Weiguo Fu, Head of Vascular Surgery of Zhongshan Hospital, and his team, achieved successful result, as no endoleak occurred and the aortic aneurysm was completely excluded. MicroPort will continue to carry out clinical trials for the device in around 15 medical centers in China.

"The success of the first implantation symbolizes the official kickoff of the pre-market clinical studies for Ultra Low Profile to ensure its safety and efficacy," said Zhenghua Miao, General Manager of MicroPort Endovascular. "We hope more patients can benefit from the device in the near future."